Clinical Trial With Aconite Pain Oil in Oncology Patients Under Chemotherapy to Prevent CIPN, to Reduce Symptoms and to Improve the Quality of Life of Patients With CIPN

Clinical Trial With Aconite Pain Oil in Oncological Patients Undergoing Chemotherapy to Prevent Chemotherapy-induced Polyneuropathy (CIPN), to Reduce Symptoms Typical of CIPN and to Improve the Quality of Life of Patients With CIPN

The clinical trial is planned as a prospective, multicentre, blinded, randomised, placebo-controlled, national clinical trial in Germany. The clinical trial is designed for testing the prophylactic and therapeutic effects of Aconite pain oil as compared to placebo in oncological patients receiving neurotoxic chemotherapy with taxanes and/or platinum derivatives.

Study Overview

• Status: Recruiting
• Conditions: Chemotherapy-induced Polyneuropathy
• Intervention / Treatment: Drug: Aconite pain oil; Drug: Placebo

• Study Type: Interventional
• Enrollment (Estimated): 350
• Phase: Phase 3

Contacts and Locations

• Study Contact: Name: Florian Stintzing, Prof. Dr.; Phone Number: 0497164930-0; Email: klin-pruef-klifo@wala.de

Study Locations

• Germany
  • Mannheim, Germany, 68167
    • Recruiting
    • Medizinische Fakultät Mannheim der Uniklinik Heidelberg
    • Contact: R.-D. Hofheinz, Prof. Dr.

Participation Criteria

Eligibility Criteria

• Ages Eligible for Study: Adult; Older Adult
• Accepts Healthy Volunteers: No

Description

Inclusion Criteria:

1. A consent form, fully dated and signed by the patient and the principal investigator/investigator, is available
2. Patients with a minimum age of 18 years
3. Patients with a Karnofsky Index ≥ 70%
4. Patients with an assumed life expectancy of at least 12 months
5. Patients with solid tumours
6. Patients who are scheduled to receive unmodified chemotherapy with taxanes or platinum derivatives or their combination approved in Germany for at least 3 months (3 lunar months / 12 weeks)
7. Patients of childbearing age must provide a negative pregnancy test

Exclusion Criteria:

1. Participation in an interventional trial (with an investigational product) that is concurrent or occurred within 4 weeks prior to inclusion in this trial
2. Pregnant and breastfeeding patients or patients who are not using effective contraception (Pearl index < 1)
3. Patients treated with topical and/or internally administered medicinal products or cosmetics containing aconite (Aconitum napellus), camphor (Camphora), lavender essential oil (Lavandulae aetheroleum), and/or quartz within 4 weeks prior to inclusion in this trial
4. Patients with known hypersensitivity to camphor and/or any of the other ingredients of Aconite Pain Oil, as well as peanut or soy
5. Patients who are not expected to be able to comprehend the significance of the clinical trial, to demonstrate the necessary compliance, and/or to complete the patient questionnaire and patient diary in the German-language for language-related, cognitive, or other reasons
6. Patients with a planned application of chemotherapy at ≥4-week intervals
7. Patients with alcohol/drug/medication dependency
8. Patients with known genetic predispositions to polyneuropathies
9. Patients with previous or current polyneuropathy irrespective of cause
10. Patients with previous or current neurotoxic medication outside the planned chemotherapy protocol that has an impact on the primary endpoint (at the investigator´s discretion) and prior taxane and/or platinum derivative administration

11. Patients with the following known comorbidities that predispose them to CIPN:

    inadequately substituted hypothyroidism, renal insufficiency grade 4 and above, vasculitis/collagenosis, inadequately treated diabetes mellitus

12. Patients with active and/or clinically relevant infectious diseases: HIV, Lyme disease, hepatitis B/C, herpes infections
13. Known presence of multiple myeloma or non-Hodgkin's lymphoma
14. Present neurological diseases, Alzheimer's disease, multiple sclerosis, Parkinson's disease, and other neurological diseases that make it difficult or impossible to assess the primary endpoint according to the investigator's opinion
15. Patients with metastases in the central nervous system
16. History of amputation of extremities
17. Patients with distal muscle weakness and/or atrophy
18. Skin lesions or other findings in the area of the extremities that make it impossible to use the investigational product (e.g., hand-foot syndrome)
19. Presence of any other serious acute or chronic organic or mental illness with severe impairment of the general condition that impairs or prevents regular participation in the trial
20. Use of co-analgesics such as gabapentin, pregabalin, amitriptyline, nortriptyline, clomipramine, imipramine, duloxetine 1 week before commencement of the trial (baseline) and intake during the trial before reaching CIPN grade III
21. Planned acupuncture for the treatment of CIPN during the trial
22. Topical application of substances such as lidocaine, capsaicin, botulinum toxin, amitriptyline, menthol to hands and/or feet up to 1 week before trial entry (baseline) and application during the trial
23. Electrotherapy on the extremities up to 1 week before the start of the trial (baseline) and during the trial

Study Plan

How is the study designed?

Design Details

• Primary Purpose: Prevention
• Allocation: Randomized
• Interventional Model: Parallel Assignment
• Masking: Triple

Number of Arms

2

Arms and Interventions

Participant Group / Arm	Intervention / Treatment
Placebo Comparator: Placebo	Drug: Placebo; Participants apply 6 ml oil topically 2 times per day (morning and evening) for 15 to 27 weeks on chemotherapy-free days as long as they receive chemotherapy.
Experimental: Verum	Drug: Aconite pain oil; Participants apply 6 ml oil topically 2 times per day (morning and evening) for 15 to 27 weeks on chemotherapy-free days as long as they receive chemotherapy.

What is the study measuring?

Primary Outcome Measures

Outcome Measure	Measure Description	Time Frame
The date of occurrence of CIPN by the principal investigator/investigator using the EORTC-QLQ-CIPN20		on average every 3 weeks for max. 27 weeks
Percentage of CIPN measured by "Common Terminology Criteria for Adverse Events" (CTC-AE v4.0 of 2010)	for neuralgia, paraesthesia, peripheral motor polyneuropathy, peripheral sensory polyneuropathy	on average every 3 weeks for max. 27 weeks

Collaborators and Investigators

• Sponsor: WALA Heilmittel GmbH

Study record dates

Study Major Dates

• Study Start (Actual): March 13, 2024
• Primary Completion (Estimated): September 1, 2027
• Study Completion (Estimated): September 1, 2027

Study Registration Dates

• First Submitted: November 27, 2023
• First Submitted That Met QC Criteria: December 29, 2023
• First Posted (Actual): January 2, 2024

Study Record Updates

• Last Update Posted (Actual): August 25, 2026
• Last Update Submitted That Met QC Criteria: August 21, 2026
• Last Verified: August 1, 2026

More Information

Terms related to this study

• Additional Relevant MeSH Terms: Nervous System Diseases; Neuromuscular Diseases; Peripheral Nervous System Diseases; Polyneuropathies; Substandard Drugs; Pharmaceutical Preparations; Counterfeit Drugs
• Other Study ID Numbers: kp-acs-2

Drug and device information, study documents

• Studies a U.S. FDA-regulated drug product: No
• Studies a U.S. FDA-regulated device product: No